Catalyst Biosciences Inc. | Mutual Funds
Mutual Funds that own Catalyst Biosciences Inc.
Vanguard Total Stock Market Index Fund
322,900
2.7%
0
0%
07/31/2018
iShares Russell 2000 ETF
248,812
2.08%
-132
0.01%
09/06/2018
Eventide Healthcare & Life Sciences Fund
246,000
2.06%
246,000
0.39%
06/29/2018
Vanguard Extended Market Index Fund
162,911
1.36%
0
0%
07/31/2018
iShares Russell 2000 Value ETF
110,646
0.93%
0
0.01%
09/06/2018
SEI Institutional Managed Trust-Tax Managed Small/Mid Cap Fund
73,428
0.62%
73,428
0.06%
08/31/2018
DFA US Targeted Value Portfolio
56,455
0.47%
0
0.01%
04/30/2018
Fidelity Spartan Extended Market Index Fund
56,215
0.47%
0
0%
07/31/2018
DFA US Small Cap Portfolio
49,140
0.41%
0
0%
04/30/2018
iShares Micro Cap ETF
31,748
0.27%
0
0.03%
09/06/2018
| Address |
611 Gateway Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.catalystbiosciences.com |
| Updated |
07/08/2019 |
| Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. |
